These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 34689306)
1. A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas. Dixit KS; Sachdev S; Amidei C; Kumthekar P; Kruser TJ; Gondi V; Grimm S; Lukas RV; Nicholas MK; Chmura SJ; Fought AJ; Mehta M; Raizer JJ J Neurooncol; 2021 Dec; 155(3):297-306. PubMed ID: 34689306 [TBL] [Abstract][Full Text] [Related]
2. Outcomes of salvage fractionated re-irradiation combined with bevacizumab for recurrent high-grade gliomas that progressed after bevacizumab treatment*. Yonezawa H; Ohno M; Igaki H; Miyakita Y; Takahashi M; Tamura Y; Shima S; Matsushita Y; Ichimura K; Narita Y Jpn J Clin Oncol; 2021 Jul; 51(7):1028-1035. PubMed ID: 33959771 [TBL] [Abstract][Full Text] [Related]
3. Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas. Hundsberger T; Brügge D; Putora PM; Weder P; Weber J; Plasswilm L J Neurooncol; 2013 Mar; 112(1):133-9. PubMed ID: 23314822 [TBL] [Abstract][Full Text] [Related]
4. Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment. Shi W; Blomain ES; Siglin J; Palmer JD; Dan T; Wang Y; Werner-Wasik M; Glass J; Kim L; Bar Ad V; Bhamidipati D; Evans JJ; Judy K; Farrell CJ; Andrews DW J Neurooncol; 2018 Mar; 137(1):171-177. PubMed ID: 29235052 [TBL] [Abstract][Full Text] [Related]
5. Hypofractionated re-irradiation with bevacizumab for relapsed chemorefractory glioblastoma after prior high dose radiotherapy: a feasible option for patients with large-volume relapse. Tong E; Horsley P; Wheeler H; Wong M; Venkatesha V; Chan J; Kastelan M; Back M J Neurooncol; 2024 May; 168(1):69-76. PubMed ID: 38551747 [TBL] [Abstract][Full Text] [Related]
6. Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas. Peters KB; Lipp ES; Miller E; Herndon JE; McSherry F; Desjardins A; Reardon DA; Friedman HS J Neurooncol; 2018 Apr; 137(2):349-356. PubMed ID: 29264836 [TBL] [Abstract][Full Text] [Related]
7. Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial. van den Bent MJ; Klein M; Smits M; Reijneveld JC; French PJ; Clement P; de Vos FYF; Wick A; Mulholland PJ; Taphoorn MJB; Lewis J; Weller M; Chinot OL; Kros JM; de Heer I; Verschuere T; Coens C; Golfinopoulos V; Gorlia T; Idbaih A Lancet Oncol; 2018 Sep; 19(9):1170-1179. PubMed ID: 30115593 [TBL] [Abstract][Full Text] [Related]
8. Comparison between Reirradiation by Stereotactic Body Radiation Therapy and Moderately Hypofractionated Radiotherapy in Combination with Temozolomide for Treatment of Recurrent High Grade Glioma. Saad E; Abdelwahed M; Moussa R; Abdulla M Asian Pac J Cancer Prev; 2024 Jul; 25(7):2499-2507. PubMed ID: 39068585 [TBL] [Abstract][Full Text] [Related]
9. Re-irradiation strategies in combination with bevacizumab for recurrent malignant glioma. Schnell O; Thorsteinsdottir J; Fleischmann DF; Lenski M; Abenhardt W; Giese A; Tonn JC; Belka C; Kreth FW; Niyazi M J Neurooncol; 2016 Dec; 130(3):591-599. PubMed ID: 27599828 [TBL] [Abstract][Full Text] [Related]
10. Re-irradiation treatment regimens for patients with recurrent glioma - Evaluation of the optimal dose and best concurrent therapy. Fleischmann DF; Gajdi L; Corradini S; Schönecker S; Marschner S; Bodensohn R; Hofmaier J; Garny S; Forbrig R; Thon N; Belka C; Niyazi M Radiother Oncol; 2024 Oct; 199():110437. PubMed ID: 39013502 [TBL] [Abstract][Full Text] [Related]
11. Cs-131 brachytherapy for patients with recurrent glioblastoma combined with bevacizumab avoids radiation necrosis while maintaining local control. Wernicke AG; Taube S; Smith AW; Herskovic A; Parashar B; Schwartz TH Brachytherapy; 2020; 19(5):705-712. PubMed ID: 32928486 [TBL] [Abstract][Full Text] [Related]
12. Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone. Arvold ND; Shi DD; Aizer AA; Norden AD; Reardon DA; Lee EQ; Nayak L; Dunn IF; Golby AJ; Johnson MD; Claus EB; Chiocca EA; Ligon KL; Wen PY; Alexander BM J Neurooncol; 2017 Dec; 135(3):581-591. PubMed ID: 28975467 [TBL] [Abstract][Full Text] [Related]
13. Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study. Sahebjam S; Forsyth PA; Tran ND; Arrington JA; Macaulay R; Etame AB; Walko CM; Boyle T; Peguero EN; Jaglal M; Mokhtari S; Enderling H; Raghunand N; Gatewood T; Long W; Dzierzeski JL; Evernden B; Robinson T; Wicklund MC; Kim S; Thompson ZJ; Chen DT; Chinnaiyan P; Yu HM Neuro Oncol; 2021 Apr; 23(4):677-686. PubMed ID: 33173935 [TBL] [Abstract][Full Text] [Related]
14. Initial results of a phase II trial of Breen WG; Youland RS; Giri S; Jacobson SB; Pafundi DH; Brown PD; Hunt CH; Mahajan A; Ruff MW; Kizilbash SH; Uhm JH; Routman DM; Jones JE; Brinkmann DH; Laack NN J Neurooncol; 2022 Jul; 158(3):323-330. PubMed ID: 35583721 [TBL] [Abstract][Full Text] [Related]
15. Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the Radiation Oncology Italian Association (AIRO). Navarria P; Minniti G; Clerici E; Tomatis S; Pinzi V; Ciammella P; Galaverni M; Amelio D; Scartoni D; Scoccianti S; Krengli M; Masini L; Draghini L; Maranzano E; Borzillo V; Muto P; Ferrarese F; Fariselli L; Livi L; Pasqualetti F; Fiorentino A; Alongi F; di Monale MB; Magrini S; Scorsetti M J Neurooncol; 2019 Mar; 142(1):59-67. PubMed ID: 30515706 [TBL] [Abstract][Full Text] [Related]
16. Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma. Clarke J; Neil E; Terziev R; Gutin P; Barani I; Kaley T; Lassman AB; Chan TA; Yamada J; DeAngelis L; Ballangrud A; Young R; Panageas KS; Beal K; Omuro A Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):797-804. PubMed ID: 28870792 [TBL] [Abstract][Full Text] [Related]
17. Outcome of Second Line Treatment of Recurrent High- Grade Glioma by re-Irradiation or Bevacizumab-based Chemotherapy: A Cross Sectional Study. Anvari K; Shahabadi M; Welsh JS; Javadinia SA; Zarei E Asian Pac J Cancer Prev; 2023 May; 24(5):1507-1511. PubMed ID: 37247269 [TBL] [Abstract][Full Text] [Related]
18. Reirradiation with concurrent bevacizumab for recurrent high-grade gliomas in adult patients. Schernberg A; Dhermain F; Ammari S; Dumont SN; Domont J; Patrikidou A; Pallud J; Dezamis É; Deutsch É; Louvel G Cancer Radiother; 2018 Feb; 22(1):9-16. PubMed ID: 29217134 [TBL] [Abstract][Full Text] [Related]